Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Tau-targeting therapy reduces epilepsy and autism behaviors in model of Dravet syndrome

June 3, 2022

Kavli Neuroscience Prize honors four for genetic discoveries

June 2, 2022

ATAD3A is a therapeutic target in Alzheimer's disease

June 2, 2022

Close look illuminates ketamine's (relative) staying power

June 1, 2022

Artemisinin derivatives as potential agents for the treatment of MS

June 1, 2022

Studies identify chronic pain mechanisms in skin and spinal cord

May 31, 2022

PharmEnable and Denali Therapeutics to collaborate in neurodegenerative disease research

May 31, 2022

Boehringer Ingelheim presents new indoleamine 2,3-dioxygenase 1 inhibitors

May 31, 2022

Suzhou Yabao Pharmaceutical Research and Development patents mutant LRRK2 inhibitors

May 31, 2022

NRG Therapeutics receives Biomedical Catalyst award for neurodegenerative disorders

May 31, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...